TransCode Therapeutics(RNAZ.US)

Last Updated 19:00:00 ET
longbridge loading

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

rttnews·
US
SI
-0.32%
US
RNAZ
-6.33%
US
TMCI
+3.84%
rttnews·
US
SI
-0.32%
US
RNAZ
-6.33%
US
TMCI
+3.84%

TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock News

StockTitan·
US
RNAZ
-6.33%
StockTitan·
US
RNAZ
-6.33%

TransCode Therapeutics shares are trading lower. The company announced Phase 1a dose escalation clinical trial update showing safety, tolerability, and disease stabilization with its lead candidate TTX-MC138.

benzinga_article·
US
RNAZ
-6.33%
benzinga_article·
US
RNAZ
-6.33%

Pre-Market Movers: PMI, CNTB, RNAZ Chart The Course

nasdaq·
US
RNAZ
-6.33%
US
BMGL
+2.01%
US
CNTB
+0.95%
nasdaq·
US
RNAZ
-6.33%
US
BMGL
+2.01%
US
CNTB
+0.95%

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

benzinga_article·
US
RNAZ
-6.33%
benzinga_article·
US
RNAZ
-6.33%

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | RNAZ Stock News

StockTitan·
US
RNAZ
-6.33%
StockTitan·
US
RNAZ
-6.33%
© 2026 Longbridge｜Disclaimer